L3VLUP
ProSign in

CYRX · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

CYRXLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • CYRX
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterCYRXLLY
Q3 20203 holders, $66m33 holders, $14.1bn
Q4 20203 holders, $50m29 holders, $17.3bn
Q1 20211 holders, $58m24 holders, $23.0bn
Q2 20212 holders, $63m24 holders, $27.8bn
Q3 20212 holders, $16m31 holders, $29.9bn
Q4 20211 holders, $2.9m31 holders, $34.7bn
Q1 20222 holders, $9.1m24 holders, $35.3bn
Q2 2022none listed holders, n.a.33 holders, $42.7bn
Q3 20221 holders, $801k31 holders, $43.4bn
Q4 2022none listed holders, n.a.31 holders, $46.6bn
Q1 2023none listed holders, n.a.33 holders, $44.3bn
Q2 2023none listed holders, n.a.37 holders, $59.6bn
Q3 2023none listed holders, n.a.44 holders, $67.6bn
Q4 2023none listed holders, n.a.45 holders, $73.6bn
Q1 2024none listed holders, n.a.41 holders, $95.3bn
Q2 2024none listed holders, n.a.43 holders, $110bn
Q3 2024none listed holders, n.a.45 holders, $107bn
Q4 2024none listed holders, n.a.46 holders, $93.9bn
Q1 2025none listed holders, n.a.42 holders, $98.4bn
Q2 2025none listed holders, n.a.43 holders, $93.2bn
Q3 2025none listed holders, n.a.39 holders, $86.7bn
Q4 20251 holders, $3.0m41 holders, $123bn
Q1 20261 holders, $6.2m39 holders, $106bn
Q2 20261 holders, $20m44 holders, $132bn
CYRX

Cryoport Inc

Holders
0
Reported value
$0
Buyers
n.a.
Sellers
n.a.

No cross-section for this quarter.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
41
Reported value
$95.3bn
Buyers
15
Sellers
27

Breadth -12 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2024

Among the 41 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only CYRX (0)

None.

Only LLY (41)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Artisan Partners LP, Balyasny Asset Management LLC, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, Coatue Management LLC, D. E. Shaw & Co., Dodge & Cox, Fidelity (FMR LLC), GAMCO Investors Inc, Holocene Advisors LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Moore Capital Management LP, and 16 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →